Related Experiment Video
Updated: Jun 26, 2026

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
Published on: April 4, 2025
Aldosterone and progression of kidney disease
Monica Cortinovis1, Norberto Perico, Dario Cattaneo
1Department of Medicine and Transplantation, Ospedali Riuniti di Bergamo - Mario Negri Institute for Pharmacological Research, Bergamo, Italy.
Abstract:
Experimental evidence indicates that aldosterone, besides its mineralcorticoid properties, directly contributes to accelerate renal damage through promotion of cell growth, fibrosis and inflammation. As a consequence, attenuation of growth-promoting and fibroproliferative effects of aldosterone might contribute to slow progression of chronic renal injury. Preliminary clinical observations have documented that aldosterone blockers added to angiotensin-converting enzyme inhibitor- and/or angiotensin receptor blocker-based regimens exerted significant antiproteinuric effects in patients with diabetic and nondiabetic nephropathies. Further studies in larger cohorts are now required to definitively address the safety and efficacy of aldosterone antagonism in patients with chronic kidney diseases.
Insights
Aldosterone accelerates kidney damage by promoting cell growth and fibrosis. Aldosterone blockers may slow chronic kidney disease progression and reduce proteinuria in patients with diabetic and nondiabetic nephropathies.
Area of Science:
- Nephrology
- Endocrinology
- Cardiovascular Research
Background:
- Aldosterone contributes to renal damage via cell growth, fibrosis, and inflammation.
- Reducing aldosterone's effects may slow chronic kidney disease (CKD) progression.
Purpose of the Study:
- To evaluate the potential of aldosterone antagonism in managing CKD.
- To assess the antiproteinuric effects of aldosterone blockers in nephropathies.
Main Methods:
- Review of experimental evidence on aldosterone's renal effects.
- Analysis of preliminary clinical observations of aldosterone blockers.
- Assessment of combination therapy with ACE inhibitors and/or ARBs.
Main Results:
- Aldosterone blockers demonstrated significant antiproteinuric effects.
- These effects were observed in patients with both diabetic and nondiabetic nephropathies.
- Combination therapy showed promise in reducing proteinuria.
Conclusions:
- Attenuating aldosterone's growth-promoting and fibroproliferative actions may slow CKD progression.
- Aldosterone antagonism shows potential as a therapeutic strategy for CKD.
- Larger cohort studies are needed to confirm safety and efficacy.
Related Concept Videos
Antihypertensive Drugs: Potassium-Sparing Diuretics
Chronic Kidney Disease I: Introduction
Hormonal Regulation
Introduction to Urinary System
The kidneys are bean-shaped organs located in the retroperitoneal space, on either side of the vertebral column, between the T12 and L3 vertebrae. They are partially protected by the rib cage and surrounded by perirenal fat, which provides cushioning. They are responsible for urine formation and play critical roles in regulating blood pressure, electrolyte levels, and hormone production. The ureters...
Heart Failure Drugs: Diuretics
Diabetic Nephropathy
